Skip to content

Comparative study of nanofiber drug delivery system containing brimonidine and drops in the treatment of glaucoma patients

Comparative study of nanofiber drug delivery system containing brimonidine and drops in the treatment of glaucoma patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130812014333N241
Enrollment
12
Registered
2025-03-05
Start date
2025-03-15
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma. Open-angle glaucoma

Interventions

Intervention 1: Eligible individuals will initially be considered as the control group and will receive placebo or standard interventions (brimonidine drops are administered for one week). After the t

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: Over 20 years old P-OAG patients with pressures greater than 21 Patients with unilateral or bilateral glaucoma whose eye pressure is controlled with a medication

Exclusion criteria

Exclusion criteria: Patients with a history of glaucoma surgery Pregnant and breastfeeding women History of the ban on the use of brimonidine Patients with eyelid problems Patients with a history of argon laser trabeculoplasty

Design outcomes

Primary

MeasureTime frame
Intraocular pressure. Timepoint: At the beginning of the study, daily at a specific time of 9-10 am and 9-10 pm for one month. Method of measurement: Intraocular pressureUsing Goldmann Applanation Tonometer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fariba Sheikhishoushtari

Kermanshah University of Medical Sciences

fshaikhi@kums.ac.ir+98 83 3729 6591

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026